1. (valid email required)

cforms contact form by delicious:days

GlaxoSmithKline, AstraZeneca and other Pharmaceutical Leaders Reduce R&D Time and Costs Using AspenTech’s Software

August 19, 2010

Industry Collaboration Results in Newly Patented Technology that Helps Drug Companies Comply with Latest Regulatory “Quality by Design” Initiatives

Burlington, Mass – July19th, 2010- Aspen Technology, Inc. (NASDAQ: AZPN), a leading provider of software and services to the process industries, today announced that GlaxoSmithKline, AstraZeneca and other pharmaceutical industry leaders are reducing their research and development time and costs using newly patented technology that is part of AspenTech’saspenONE Process Development for Pharmaceuticals software.

Supporting Quotes:
Stephen Carino, Investigator – Solid Form Sciences Group, GlaxoSmithKline
“Screening for crystalline forms is an essential component in pharmaceutical drug development. In our high-throughput screening workflow, we have utilized NRTL-SAC in Aspen Properties to predict the equilibrium solubility of the drug in single- and multi-component solvent systems. The predicted solubility values are used in selecting an appropriate set of solvent systems that are explicitly unique for each of the crystallization modes. This rational solvent selection coupled with the systematic screening approach has allowed us to assess risk around solid forms and improve our confidence in the robustness of the API processes.”

Jamie Hintlian, Vice President of Pharmaceuticals, Aspen Technology, Inc.
“Solubility is essential in evaluating drug candidacy and manufacturability. Without predictive tools, many organizations are forced to fly blind when it comes to this mission-critical information. Solubility modeling and prediction adds value by enabling greater efficiencies, better decision making, faster process development, and better process performance. For the pharmaceutical industry leaders involved in its development, and other potential users, this is a powerful screening protocol for the drug development process.”

Supporting Resources:

About AspenTech
AspenTech is a leading supplier of software that optimizes process manufacturing – for energy, chemicals, pharmaceuticals, engineering and construction, and other industries that manufacture and produce products from a chemical process. With integrated aspenONE solutions, process manufacturers can implement best practices for optimizing their engineering, manufacturing and supply chain operations. As a result, AspenTech customers are better able to increase capacity, improve margins, reduce costs and become more energy efficient. To see how the world’s leading process manufacturers rely on AspenTech to achieve their operational excellence goals, visit www.aspentech.com.

Latest News

Dynasil Corporation of America (NASDAQ:DYSL) is pleased to announce our new website is now available at www.dynasil.com

NWN Corporation Obtains Cisco’s Elite Partnership Status In Their OpenDNS Certification Partner Program

NWN Corporation Named to CRN’s 2016 IT Solutions Provider 500 List

ACT Government leads in waste innovation

Zenoss Names NWN Corporation as Managed IT Service Provider of The Year For Second Year In a Row

Datawatch Enables 450 CNAF Accountants to Prep Less and Analyze More

NWN Completes “Cisco Mega Audit” – Achieves Multiple “Master” Certifications

Best Practices for Pharmaceutical Waste

Latest Newsletters

July 2016 – Mass Capital Announces a New Investment in The Cadmus Group, Inc.

April 2016 – Andrew DeLorey joins Mass Capital

March 2016 – Mass Capital announces a new investment in Valet Park of America

January 2016 – Mass Capital announces a new investment in Phillips Screw Company

November 2015 – Mass Capital announces a new investment in Triumvirate Environmental

September 2015 – Mass Capital announces a new investment in MedTouch

September Newsletter 2014

Mass. Capital Announces Addition to Investment Team